Albireo to present at the william blair biotech focus conference 2022

Boston, june 30, 2022 (globe newswire) -- albireo pharma, inc. (nasdaq: albo), a rare liver disease company developing novel bile acid modulators, today announced participation at the william blair biotech focus conference july 12-13, 2022. ron cooper, president and chief executive officer, will take part in a fireside chat during the conference. ron and simon harford, chief financial officer, will also host meetings during the conference.
ALBO Ratings Summary
ALBO Quant Ranking